Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of EBITDA Margin data on record, last reported at 9267.68% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 814171.0% year-over-year to 9267.68%; the TTM value through Sep 2025 reached 1588.37%, down 34363.0%, while the annual FY2024 figure was 1361.83%, 17204.0% up from the prior year.
  • EBITDA Margin reached 9267.68% in Q3 2025 per DNTH's latest filing, up from 16477.2% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 465.36% in Q4 2024 and bottomed at 16477.2% in Q2 2025.
  • Average EBITDA Margin over 4 years is 3319.34%, with a median of 1489.23% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 200225bps in 2024, then plummeted -1553158bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 874.53% in 2022, then plummeted by -182bps to 2467.61% in 2023, then soared by 81bps to 465.36% in 2024, then crashed by -1892bps to 9267.68% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 9267.68% in Q3 2025, 16477.2% in Q2 2025, and 2523.39% in Q1 2025.